Clinical trials located in

Bielefeld

Bielefeld city is located in Germany. Currently, 18 clinical trials are being conducted in this city.

Bielefeld, located in North Rhine-Westphalia, Germany, is a city steeped in history and culture. Founded in 1214, it is home to the Sparrenburg Castle, a medieval fortress offering panoramic views. Bielefeld is also known for its significant role in the linen industry, contributing to its economic growth. The city houses the University of Bielefeld, recognized for its interdisciplinary research. An intriguing aspect of Bielefeld is the “Bielefeld Conspiracy,” a satirical theory denying the city’s existence, which has become a part of popular culture.

  • CT-EU-00054021

    Improving psoriasis treatment for patients: a study on brodalumab

    This detailed study focuses on individuals with moderate-to-severe plaque psoriasis who weigh more than 120 kg. It aims to find out if adjusting the dose of the medication brodalumab can lead to better skin health. In this study, participants receive either an adjusted higher dose of brodalumab or the standard dose. Researchers closely monitor the skin’s response to the treatment, checking if the adjusted dose leads to better skin clearance, meaning fewer or no psoriasis symptoms.

    BelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandSpainUnited Kingdom
  • New lung cancer study: testing osimertinib before surgery

    The aim of this clinical trial is to evaluate the effectiveness of osimertinib, a drug that specifically targets the EGFR mutation, in patients with resectable non-small cell lung cancer. The study will involve three groups: one will receive standard chemotherapy, the second will receive a combination of osimertinib and chemotherapy, and the third will receive osimertinib alone. This phase III trial focuses on patients with a specific genetic mutation (EGFRm) in lung cancer. Key outcomes measured include tumor removal rate, survival rates and overall quality of life. The aim is to improve the standard of pre-operative treatment, which could potentially lead to better outcomes for lung cancer patients. The study also aims to understand the impact of osimertinib on this disease, particularly when combined with traditional chemotherapy, which will provide a comprehensive picture of potential benefits and risks.

    AustriaBulgariaFranceGermanyItalyPolandSpainUnited Kingdom
  • Examining ultrasound-assisted and standard treatment for lung clots

    In this study, researchers want to compare two treatments for a disease called pulmonary embolism. This is a disease in which a blood clot blocks the vessels that supply blood to the lungs. The group of people taking part in the study will be randomly assigned to receive either blood-thinning medications alone (anticoagulation) or blood-thinning medications using a blood clot-dissolving device. The name of this device is the EkoSonic endovascular device. The research will continue for 12 months, and the health of the participants will be regularly monitored.

    AustriaFranceGermanyNetherlandsPolandUnited Kingdom
  • Testing mavacamten for heart muscle disease

    This study aims to assess a drug called Mavacamten for a heart condition called Non-Obstructive Hypertrophic Cardiomyopathy. Patients will be randomly given either the actual drug or a placebo without anyone knowing which one they’ve received. The study will measure how safe and effective the drug is for patients with symptoms of this heart condition. The success of the drug will be determined by preventing heart-related issues such as heart attacks, strokes, heart failures, irregular heartbeats, and the need for a heart-rhythm controlling device.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsNorwayPolandPortugalSpainUnited Kingdom
  • Fenfluramine Hydrochloride study for seizure control in cyclin-dependent kinase like-5 (CDKL5)

    This is studying a new substance called Fenfluramine Hydrochloride (ZX008) in children and adults experiencing seizures with cyclin-dependent kinase like-5 (CDKL5) deficiency disorder (CDD). The research has two parts. In the first part, lasting 20 weeks, some participants receive the new drug, while others receive a placebo (inactive substance). This part aims to determine if ZX008 is effective and safe. The second part lasts 54 weeks and is open-label, meaning everyone is aware they are receiving the active drug. It helps assess long-term effects. If participants complete the first part, they can enroll in the second part, including an open-label treatment period (52 weeks) and a taper period (2 weeks).

    AustriaBelgiumGermanyNetherlandsPortugalSpainUnited Kingdom
  • Testing tovorafenib in treating low-grade glioma

    This study is a comparative test between tovorafenib (DAY101) and the standard chemotherapy typically administered to children with low-grade glioma, a specific type of brain tumor. The experiment involves approximately 400 children who have not yet received treatment for their glioma. The participants will be divided into two groups. In the first group, children will be administered DAY101, taking it every 28 days until one of the following events occurs: they no longer benefit from the treatment, it becomes unsafe, they choose to leave the experiment, or the experiment concludes. In the second group, children will receive one of three common chemotherapy drugs selected by their doctor, and they will continue with the treatment until similar circumstances prompt a change, as outlined for the first group. If the tumor continues to grow while on DAY101 but the treatment remains beneficial, participants can continue taking it. Likewise, if the tumor continues to grow while on chemotherapy, participants can stop and transition to DAY101.

    AustriaBelgiumCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwaySloveniaSpainSwedenUnited Kingdom
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Testing the safety and efficacy of Ruxolitinib cream in prurigo nodularis therapy

    This clinical trial is to test a cream with Ruxolitinib on people with a skin condition called prurigo nodularis (PN) over a period of about one year. The trial is divided into three stages. In the first 12 weeks, participants will use either the Ruxolitinib cream or a placebo cream on the skin where PN appears. In the next 40 weeks, the Ruxolitinib cream will only be applied to the areas where PN is active. The last 30 days are to watch for any side effects. The trial will monitor changes in the severity of itching and the number of PN bumps on the skin. Any possible side effects will be recorded too.

    AustriaBulgariaDenmarkFranceGermanyItalyPolandSpain
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Enhancing seizure control: Soticlestat’s impact in Dravet and Lennox-Gastaut Syndromes

    This trial examines soticlestat as an additional therapy for children and adults with Dravet Syndrome or Lennox-Gastaut Syndrome, aiming to reduce seizure frequency. Participants, continuing their standard anti-seizure treatments, receive soticlestat tablets, with the study monitoring seizure reduction and overall health impacts, offering hope for better seizure management in these conditions.

    BelgiumFranceGermanyGreeceHungaryItalyNetherlandsPolandSpain
  • Comparing atogepant and topiramate for migraine prevention

    In this study, a comparison is being made between two different medicines aimed at preventing migraines in adults. Migraines manifest as severe headaches on one side of the head, accompanied by symptoms such as nausea, throbbing pain, or sensitivity to light and sound. The two medicines under comparison are named atogepant and topiramate. Atogepant is currently employed for migraine prevention in individuals experiencing migraines from 0 to 14 days per month, and the study seeks to evaluate its potential broader application. Topiramate is already widely utilized for migraine prevention. Participants in this study will be divided into two groups: one group will be administered atogepant, while the other will receive topiramate for a duration of 24 weeks. Following this period, those eligible to continue will all receive atogepant for an additional 52 weeks. The study will assess their progress and monitor any potential side effects.

    AustriaBelgiumCzechiaFranceGermanyHungaryItalyPolandPortugalUnited Kingdom
  • Evaluation of the effectiveness of combined therapy in the treatment of bladder cancer with muscle invasion

    This clinical study, known as the VOLGA trial, is for bladder cancer patients who cannot or refuse to take Cisplatin. Two new therapy combinations are being tested. The first combines Durvalumab, Tremelimumab, and Enfortumab Vedotin. The second partners Durvalumab with Enfortumab Vedotin only. Patients receive these drugs both before and after having bladder surgery. This study wants to involve about 830 patients and will assign them blindly to the therapy combinations. Patients will receive the blend for three cycles, with more Durvalumab treatments after surgery. We want to track if the cancer is eradicated after surgery, when the cancer appears again, the survival rate, unwanted effects, and the patients’ well-being. Taking part in this study might require commitment for approximately 3-5 years, with follow-ups to monitor the patient’s progress.

    AustriaFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Myeloma study: lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab

    A groundbreaking study for newly diagnosed multiple myeloma patients is assessing whether a subcutaneous form of the drug isatuximab is as effective as the intravenous version. This study combines isatuximab with three other medications, lenalidomide, dexamethasone and bortezomib, in an approach known as induction therapy. The goal is to enhance patient comfort and maintain treatment effectiveness, potentially leading to an excellent partial response or better in patients eligible for stem cell transplants.

    AustriaGermany
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain
  • Comparison of milvexian and apixaban in reducing stroke risk in patients with atrial fibrillation

    This study is designed to compare two drugs, Milvexian and Apixaban to reduce the potential risk of stroke for patients suffering from atrial fibrillation, a common heart rhythm disorder. 15500 participants, aged 18 years and older will be invited to partake in this research. Participants will be randomly designated to receive either Milvexian or Apixaban. The study team aims to determine if Milvexian is at least as effective as Apixaban in reducing the risk of combined stroke and Non-central nervous system (CNS) systemic embolism. Furthermore, the research team will evaluate the occurrence rates of various health incidents including major bleeding, various cardiovascular complications, death, and other severe conditions over a 4-year period. The goal is to find out which medication proves safer and more effective in preventing severe health risks linked with this disorder. Study commencement is April 11, 2023, with completion targeted at May 5, 2027.

    BelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Exploring the impact of SanaCutan Basiscreme in delaying atopic dermatitis in high-risk children.

    The trial focuses on evaluating a preventive approach for atopic dermatitis, a common skin disease, in high-risk newborns. These selected infants are at an increased risk due to familial history. The trial involves the application of SanaCutan Basiscreme – a moisturizing cream already approved for treating various skin ailments – on their skin twice daily until they reach 6 months old, with some continuing this treatment until the end of their first year. In parallel, a control group is instructed to avoid the use of skincare products. Any skin issues that appear in either group will be documented and medical examination will be performed regularly. The ultimate goal is to observe if the application of the cream can delay the onset of atopic dermatitis symptoms in these children beyond the first 6 or 12 months of their life.

    Germany

See more clinical trials in other cities in Germany:

.